Article

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?

2026-07-17

Abstract excerpt

Molecular residual disease (MRD) testing approaches with plasma next-generation sequencing (NGS) testing to identify circulating tumor DNA (ctDNA) in resectable stage non-small cell lung cancer (NSCLC) are evolving. The MRD concept is to better guide perioperative systemic treatment and identify recurrent NSCLC before symptomatic radiographic recurrences. Multiple tumor-informed assays are available with technolog...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e583641b-4f7a-52d7-930a-80a0769ddaa5
DOI: 10.20944/preprints202607.1334.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?DOI 10.20944/preprints202607.1334.v1Read

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Semantic proximity Read

Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification.Semantic proximity Read

Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.Semantic proximity Read

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Semantic proximity Read

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual DiseaseSemantic proximity Read

Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA FragmentomicsSemantic proximity Read

Dynamic Surveillance of Minimal Residual Disease via a Tumor-Informed Circulating Tumor DNA Assay for Outcome Prediction in Small-Cell Lung Cancer: A Prospective Pilot StudySemantic proximity Read

Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.Semantic proximity Read

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.Semantic proximity Read

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read